Clinical Trial: Case Series Study of Biliary Tract Cancer Patients in Japan
Study Status: Completed
Recruit Status: Completed
Study Type: Observational
Official Title: Retrospective Analysis of the Difference of Prognosis Between Unresectable and Recurrent Biliary Tract Cancer
Brief Summary: To assess the difference of prognosis between unresectable and recurrent biliary tract cancer and evaluate prognostic factors.
Detailed Summary: Most patients of biliary tract cancer have advanced disease at diagnosis and often relapse despite surgery. Combination therapy of gemcitabine and cisplatin could be a standard therapy for this kind of cancer with the evidence of phase III study compared with gemcitabine alone. However the prognosis and the tolerability of chemotherapy in the patients with recurrent biliary tract cancer after radical resection might differ from those of unresectable biliary tract cancer, because the dose intensity of chemotherapy can be influenced by adjuvant chemotherapy and/or hepatic resection.
Sponsor: Kansai Hepatobiliary Oncology Group
Current Primary Outcome: One year survival rate [ Time Frame: 1 year ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
- Overall survival time [ Time Frame: 3 years ]
- Number of participants with adverse events [ Time Frame: 3 years ]
- Progression free survival [ Time Frame: 3 years ]
Original Secondary Outcome: Same as current
Information By: Kansai Hepatobiliary Oncology Group
Dates:
Date Received: January 3, 2011
Date Started: November 2010
Date Completion:
Last Updated: November 24, 2011
Last Verified: November 2011
